Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders.
Animals
Blood-Brain Barrier
/ metabolism
Central Nervous System Agents
/ administration & dosage
Central Nervous System Diseases
/ drug therapy
Clinical Trials as Topic
Disease Models, Animal
Humans
Nanoparticle Drug Delivery System
/ chemistry
Permeability
/ drug effects
Theranostic Nanomedicine
/ methods
Treatment Outcome
BBB
Nanoparticles
cancer.
drug delivery
imaging
neuronal disorders
theranostics
Journal
Current drug metabolism
ISSN: 1875-5453
Titre abrégé: Curr Drug Metab
Pays: Netherlands
ID NLM: 100960533
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
03
2020
revised:
04
08
2020
accepted:
08
09
2020
pubmed:
26
11
2020
medline:
28
12
2021
entrez:
25
11
2020
Statut:
ppublish
Résumé
Impressive research steps have been taken for the treatment of neurological disorders in the last few decades. Still, effective treatments of brain related disorders are very less due to problems associated with crossing the blood-brain barrier (BBB), non-specific therapies, and delay in functional recovery of the central nervous system (CNS) after treatment. Striving for novel treatment options for neurological disorders, nanotechnology- derived materials, and devices have gained ground due to inherent features of derivatization/encapsulation with drugs as per the neurological ailments and pharmacological targets. Facile developments/syntheses of the nanomaterials-drug conjugates have also been the driving force for researchers to get into this field. Moreover, the tunable size and hydro/lipophilicity of these nanomaterials are the added advantages that make these materials more acceptable for CNS disorders. These nano-neurotherapeutics (NNTs) systems provide the platform for diagnosis, theranostics, treatments, restoration of CNS disorders, and encourage the translation of NNTs from "bench to bedside". Still, these techniques are in the primary stages of medical development. This review describes the latest advancements and future scenarios of developmental and clinical aspects of polymeric NNTs.
Identifiants
pubmed: 33234099
pii: CDM-EPUB-111766
doi: 10.2174/1389200221666201124123939
doi:
Substances chimiques
Central Nervous System Agents
0
Nanoparticle Drug Delivery System
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
251-262Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.